Phase I trial of adjuvant mature autologous dendritic cell/allogeneic tumor lysate vaccines in combination with temozolomide in newly diagnosed glioblastoma.

1 Subgroup analysis based on the presence or absence of MGMT promoter methylation showed a trend to prolonged survival in patients with MGMT promoter methylation both for median PFS (19.4 vs 9.4 months) ( Figure 3C ) and OS (26.5 vs 16 months) ( Figure 3D ), as expected.

also in 53,322 other papers